Jingpai is a Chinese brand. Jingpai is an eye drop brand owned by Hubei Qianjiang Pharmaceutical Co., Ltd. Hubei Qianjiang Pharmaceutical Co., Ltd., Jingpai, one of the top ten brands of eye drops, started in 1970, is a famous trademark in Hubei Province, a high-tech enterprise, with ophthalmic drugs as its main features, lyophilized agents and APIs as its main directions. Chinese and Western medicine pharmaceutical company.

Hubei Qianjiang Pharmaceutical Co., Ltd. (hereinafter referred to as "Qianjiang Pharmaceutical") is located in Qianjiang, a star city in China known as the hometown of crayfish. Its headquarters is located in Qianjiang Pharmaceutical Biomedical Industrial Park , covering an area of ??140,000 square meters. The company was founded in the 1970s. After more than 40 years of unremitting efforts, it has now developed into a comprehensive Chinese and Western medicine pharmaceutical enterprise integrating production, academia and research, and has a subsidiary that produces APIs - Hubei Jianqi. PHARMACEUTICALS LIMITED. The company has first-class production equipment, advanced production technology, strong scientific research strength, excellent marketing team and high-quality staff, and has established a complete modern enterprise management system and process.

As a high-tech enterprise supported by the state and a national ophthalmic drug production base, Qianjiang Pharmaceutical adheres to R&D as the guide, continues to invest in R&D, and establishes close ties and cooperation with domestic and foreign R&D institutions. In October 2012 In September, it signed an agreement with the American company TNI to jointly develop anti-cancer drugs and actively integrate into the international market. The company now has 15 major dosage form production lines and 123 product specifications that have passed national GMP certification for lyophilizers, eye drops, etc.; it has an annual output of 80 million lyophilizers, 200 million small-volume injections, and 200 million tablets ( bags) solid preparations and 200 million eye drops production capacity.

The company adheres to the main features of ophthalmic drugs, lyophilized agents and APIs as the main direction, and strives to steadily promote the development of traditional pharmaceutical preparations and build an ophthalmic drug production base and an antiviral and anti-infective drug production base. , while focusing on developing high-precision new anti-tumor drugs, biomedicine and traditional Chinese medicine products to enhance the company's core competitiveness and profitability.